信息搜索
信息关键字：药
  

共有3954条记录

分页[首页] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198]

·先声药业发布2021年中报：创新药营收占比近六成研发管线进入快速进展期2021-8-26 21:23:06
·甘李药业2021年半年度净利3.73亿元同比净利增加21.17%2021-8-26 19:51:59
·生意场上无“父子”！华东医药与子公司“开撕”或每年损失5000万？3个月暴跌41%即将上市的少女针能救回来吗？2021-8-26 19:43:29
·海南海药上半年亏损3.77亿元营收10亿销售费用近3亿2021-8-26 17:46:15
·皓元医药发业绩股价跌19%半年净利不到1亿市值247亿2021-8-26 17:42:11
·顾得医药2021年上半年净利118.34万较上年同期增长1153.32%2021-8-26 13:54:27
·忙活半年只赚了100万元华北制药上半年净利润下滑99%2021-8-26 9:15:28
·长信基金安昀两混基年内跌超15%“喝酒吃药”受挫折2021-8-26 7:30:04
·8月机构调研热情大减医药生物行业仍受青睐2021-8-26 7:17:29
·共同药业2021年半年度净利4104.37万元同比净利增加119.70%2021-8-25 20:29:59
·老百姓收问询函：要求说明收购华佗药房51%股权的必要性与合理性2021-8-25 19:33:05
·以岭药业半年报业绩双增：二线产品收入翻倍式增长研发投入同比增长超40%2021-8-25 19:28:58
·以岭药业：营业收入增长30%以上一线产品持续拉动二线产品后劲十足2021-8-25 19:07:57
·仙琚制药闪崩大跌，4机构合卖1.7亿，北向资金净买688万2021-8-25 18:47:08
·华北制药：注射用阿莫西林钠克拉维酸钾通过仿制药一致性评价2021-8-25 18:11:04
·迪哲医药答科创板第三轮问询被问高管持股平台资金来源是否代持或利益安排2021-8-25 16:05:52
·中信证券：二季度科技、医药等成长板块重获美国投资机构关注2021-8-25 13:56:39
·嘉应制药监事赖义财子女短线炒公司股票赚13万元被出具监管函2021-8-25 13:19:19
·复星医药上半年净利润增长超四成研发投入力度不减2021-8-25 10:12:42
·东吴证券点评恒瑞医药2021年中报：受集采影响公司业绩承压，创新与国际化转型持续加速2021-8-25 8:52:23

分页[首页] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198]